PETMED EXPRESS INC (PETS) Form 8-K — Aug 13, 2026
PetMed Express (PETS) reported fiscal first quarter results for the period ended June 30, 2026, with net sales of $41.0 million, down 19.9% from $51.2 million a year earlier, as a decline in prescription medication sales outweighed lower consumer promotional usage. Management noted net sales have stabilized sequentially over the past several quarters. Net loss narrowed to $6.1 million, or $(0.28) per diluted share, from $34.2 million, or $(1.65), in the prior-year quarter, but the improvement was primarily due to the absence of last year's $27.3 million goodwill and trade name impairment charges. On an operating basis, adjusted EBITDA actually worsened to $(3.4) million from $(2.7) million.
Key figures
- Revenue
- 41015000
- Revenue Yoy
- -19.9%
- Total Assets
- 63762000
- Cash Position
- 13079000
- Shares Outstanding
- 21682381
- Gross Profit
- 11333000
- Cash Prior Quarter
- 21412000
- Prior Year Revenue
- 51180000
- Shareholders Equity
- 22989000
- New Customers Acquired
- 70000
- Ga Expense Reduction Yoy
- nearly 14%
- Prior Year Impairment Charge
- 27258000
- Customer Acquisition Cost Reduction Yoy
- -15%
Price after filing
Close on the filing date to close N calendar days later (from $1.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.